Guardant Health

Today, we welcomed Guardant Health’s Co-Founder and co-CEO, Helmy Eltoukhy, and the team to The Royal Marsden, Chelsea. Guardant Health is a leading industry pioneer in liquid biopsy testing and industry partner of The Royal Marsden. Our Marsden360 ctDNA test was developed by Guardant Health and implemented by The Royal Marsden’s Clinical Genomics team through an innovative tech transfer. Marsden360 is a minimally invasive liquid biopsy test, taken from a simple blood sample, that detects genetic changes in tiny amounts of circulating tumour DNA in the blood and is an example of how genomics is delivering innovation in cancer testing. The session was chaired by Professor Sanjay Popat, Consultant Medical Oncologist, Head of the Lung Unit, The Royal Marsden. At the meeting, the team from Guardant Health were joined by several consultants and clinical genomics leaders at The Royal Marsden to discuss future partnership opportunities and reflect on the achievements of our ongoing collaboration. Our long-term partnership with Guardant Health is a great example of how working with industry leaders is helping us to achieve our ambitions for genomics innovation in the UK. Helping to improve the lives of our patients now and in the future.  Find out more about Marsden360 and our work in clinical genomics: https://brnw.ch/21wXFOW

As molecular residual disease (MRD) testing becomes more integrated into clinical development, understanding the differences between tissue-informed and tissue-free approaches is essential to optimizing trial design and accelerating decision-making.   Join Arielle Medford, MD, and Derek Dustin, PhD, at 2PM PT on Monday, November 24, for an exclusive webinar exploring the latest advancements in MRD testing for breast cancer, including how tissue-free, methylation-based assays are enabling earlier detection of recurrence and improving trial efficiency.   Register: https://lnkd.in/e_tpN65P

A new era of data collaboration begins today:   We’re excited to announce the launch of the Single Namespace Working Group (SNS)—a 34-member consortium uniting leading technology, healthcare, and research organizations to establish the first open standard for exabyte-scale data interoperability. Together, we’re setting a new benchmark for secure, AI-ready data access that will accelerate insights and innovation across the global scientific community. Details: https://lnkd.in/exEUSt8q

Guardant Reveal® has officially expanded beyond MRD detection to include therapy response monitoring for patients with advanced solid tumors. With this expansion, oncologists now have a single, tissue-free solution that empowers confident, ctDNA-guided decisions across the care continuum. Powered by our Guardant Infinity™ Smart Platform, Guardant Reveal quantifies cancer with molecular precision, providing highly sensitive results in just 7 days. More details: https://lnkd.in/dkR_bwga

A new study published in The Journal of Liquid Biopsy validates the effectiveness of our Guardant Reveal® blood test in monitoring chemotherapy response across advanced cancers. The results show that Guardant Reveal can detect disease progression up to 18 months earlier than standard clinical measures, reinforcing its value in guiding more informed treatment decisions.

Real-world evidence continues to build for Shield™: A new study published in Current Medical Research and Opinion found that Shield demonstrates 95% patient adherence for colorectal cancer screening among 20,000 patients, adding to the growing body of evidence that Shield boosts screening adherence through a simple blood draw.

Tomorrow, our Co-CEO AmirAli Talasaz joins global health leaders at the Milken Institute's #MIHealthSummit for Part 1: Access Reimagined, a panel exploring how we can make health care access more personal, preventive, and proactive.   Access to care is about more than doctors, hospitals, or insurance. It’s about rethinking the entire patient journey and transforming today’s barriers into opportunities for impact.   At Guardant Health, we’re advancing that vision every day by aligning policy, advocacy, and innovation to make equitable access to innovative technologies like our Shield™ blood test the standard — not the exception.   Set a reminder to watch live tomorrow: https://lnkd.in/ePkPZAEq

This week, we reported our third quarter 2025 financial results, highlighted by 39% year-over-year revenue growth driven by strong performance across our Oncology, Screening, and Biopharma units. Our continued momentum, including surpassing $1 billion in annualized revenue this quarter, has led us to raise our full-year 2025 revenue guidance to $965–$970 million, representing 31% year-over-year growth.

Our Co-CEO AmirAli Talasaz contributed to the Milken Institute’s #PowerOfIdeas series ahead of next week’s #MIHealthSummit, highlighting how delays from the United States Preventive Services Task Force (USPSTF) are keeping millions of Americans from accessing innovative early detection tools like our Shield™ blood test that can save lives.   Aligning policy, advocacy, and innovation is key to making equitable access the standard—not the exception.   Read more: https://lnkd.in/gvjPrGJf #MIGlobal

We’re proud to announce a strategic partnership with Zephyr AI to deliver novel, scalable, and actionable insights that support biopharmaceutical innovation, reflecting our shared commitment to leveraging AI and multimodal data to advance cancer research and improve patient care. “By combining our industry-leading molecular data with Zephyr AI’s advanced analytics platform, we’re taking another major step toward realizing the full potential of precision oncology—helping our biopharma partners accelerate drug development and ultimately deliver better outcomes for patients worldwide,” added our co-CEO, Helmy Eltoukhy.